
Refer patients to a geneticist for an enzyme activity analysis if they are/have been¹:

Diagnosed with any of these disorders without confirmatory testing

Currently undergoing evaluation for any of these disorders




References: 1. Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. *Am J Med Genet A*. 2015;167A:11-25. 2. White K, Jester A, Bache CE, et al. Orthopedic management of the extremities in patients with Morquio A syndrome. *J Child Orthop*. 2014;8:295-304. 3. Bhattacharya K, Balasubramaniam S, Choy YS, et al. Overcoming the barriers to diagnosis of Morquio A syndrome. *Orphanet J Rare Dis*. 2014;9:192. 4. Montaño AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. *J Inherit Metab Dis*. 2007;30:165-174. 5. Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. *J Inherit Metab Dis*. 2013;36:309-322. 6. Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. *Curr Pharm Biotechnol*. 2011;12:931-945. 7. Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. *J Inherit Metab Dis*. 2013;36:293-307. 8. Lavery C, Hendriksz C. Mortality in patients with Morquio Syndrome A. *JIMD Rep*. 2015;15:59-66. 9. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. *Mol Genet Metab*. 2013;109:54-61. 10. Walker R, Belani KG, Braunlin EA, et al. Anaesthesia and airway management in mucopolysaccharidosis. *J Inherit Metab*.

BioMarin Pharmaceutical Australia Pty Ltd

119 Willoughby Rd, Crows Nest, NSW 2065, Ph +61 2 9967 8662, Medical Information 1800 387 876, medinfoasia@bmrn.com © 2017 BioMarin Pharmaceutical Inc. All Rights Reserved. APAC/MPSIV/0018 Rule out or confirm Morquio A with an enzyme activity analysis

BOMARIN



IS **MORQUIO A** HIDING IN YOUR PRACTICE?

BOMARIN

Diverse presentations of Morquio A can complicate patient identification

Morauio A presents similarly to other skeletal conditions¹

- These include multiple epiphyseal dysplasia (MED), spondyloepiphyseal dysplasia (SED), pseudoachondroplasia, and bilateral Legg-Calvé-Perthes disease¹
- Signs of Morquio A include skeletal dysplasia combined with nonskeletal organ system involvement, dystosis multiplex, and/or bilateral hip disease^{2,*}
- Diagnosis of Morquio A is often delayed over 2 years due to misdiagnosis^{3,4}

Nonclassical musculoskeletal presentation can include the following^{1,3,5}:

- Potential height of > 140 cm
- I Hip stiffness and pain
- Lack of overt skeletal presentation

In an international registry, 1 out of 4 Morquio A patients has a nonclassical phenotype⁴

Classical musculoskeletal presentation can include the following^{1,6}:

Height of < 120 cm

- I Overt spinal and skeletal abnormalities
- Joint laxity
- I Genu valgum
- Abnormal gait
- Chest abnormalities



MORQUIO A: RECOGNISING THE RISKS

Patients with Morquio A require disease-specific surgical plans

SURGERY CAN BE LIFE THREATENING IN PATIENTS WITH MORQUIO A⁸

 \approx 75% of patients < 12 years of age and more than 95% of patients \geq 12 years of age require surgical or medical interventions⁹


Life-threatening complications may include paralysis, heart failure, and respiratory failure¹⁰

There is high risk of anesthesia-related morbidity and mortality due to¹⁰:

- Cervical instability and myelopathy
- Compromised airways and respiratory function
- Cardiac abnormalities

a radiologist.2,10

*Patients may present with nonskeletal manifestations including respiratory, cardiovascular, visual, auditory, muscular, dental, and oral abnormalities.



Surgical complications may account for mortality in 1 out of 10 patients with Morquio A⁸

Patients with Morguio A benefit from a team of multidisciplinary specialists: a metabolic specialist or physician, a paediatrician, an orthopaedic surgeon, an anesthesiologist, a cardiologist, a respiratory physician, an ENT specialist, a neurosurgeon, and